See more : CB Financial Services, Inc. (CBFV) Income Statement Analysis – Financial Results
Complete financial analysis of Jiangsu Nanfang Medical Co., Ltd. (603880.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jiangsu Nanfang Medical Co., Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- People’s United Financial, Inc. (PBCTP) Income Statement Analysis – Financial Results
- Chi Ho Development Holdings Limited (8423.HK) Income Statement Analysis – Financial Results
- Triad Guaranty Inc. (TGIC) Income Statement Analysis – Financial Results
- Sculptor Acquisition Corp I (SCUA-WT) Income Statement Analysis – Financial Results
- Hyosung TNC Corporation (298020.KS) Income Statement Analysis – Financial Results
Jiangsu Nanfang Medical Co., Ltd. (603880.SS)
About Jiangsu Nanfang Medical Co., Ltd.
Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal products, medical proof fabrics, adhesive tapes, bandages, sports protection products, first-aid kits, and care products in China and internationally. It offers medical adhesive tapes, medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesive plasters, and masks, as well as customized products. The company was founded in 1990 and is based in Changzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 600.10M | 545.37M | 527.44M | 1.07B | 491.69M | 479.82M | 488.71M | 444.24M | 433.02M | 469.80M | 510.80M | 424.62M |
| Cost of Revenue | 566.33M | 473.18M | 418.19M | 709.14M | 385.70M | 367.27M | 359.56M | 312.76M | 298.06M | 334.76M | 378.94M | 320.62M |
| Gross Profit | 33.76M | 72.19M | 109.25M | 363.26M | 105.99M | 112.55M | 129.15M | 131.48M | 134.96M | 135.04M | 131.86M | 104.00M |
| Gross Profit Ratio | 5.63% | 13.24% | 20.71% | 33.87% | 21.56% | 23.46% | 26.43% | 29.60% | 31.17% | 28.74% | 25.81% | 24.49% |
| Research & Development | 28.18M | 27.73M | 30.62M | 33.96M | 22.30M | 20.09M | 19.91M | 18.82M | 19.02M | 19.01M | 0.00 | 0.00 |
| General & Administrative | 18.01M | 15.97M | 29.30M | 18.92M | 11.92M | 16.48M | 10.81M | 16.40M | 19.59M | 17.15M | 48.22M | 41.83M |
| Selling & Marketing | 7.73M | 7.19M | 9.16M | 116.45M | 11.88M | 13.67M | 13.19M | 7.90M | 8.65M | 8.54M | 7.84M | 6.57M |
| SG&A | 25.74M | 23.16M | 38.46M | 135.37M | 23.79M | 30.15M | 24.00M | 24.30M | 28.23M | 25.69M | 56.06M | 48.40M |
| Other Expenses | 126.67M | 36.43M | 35.69M | 36.10M | 23.03M | -758.02K | -44.38K | 1.34M | 1.11M | 2.07M | 1.52M | -3.64M |
| Operating Expenses | 180.59M | 87.31M | 104.78M | 205.44M | 69.13M | 73.54M | 69.15M | 66.69M | 67.52M | 59.39M | 58.87M | 50.29M |
| Cost & Expenses | 746.92M | 560.49M | 522.97M | 914.58M | 454.83M | 440.81M | 428.71M | 379.45M | 365.58M | 394.16M | 437.80M | 370.91M |
| Interest Income | 840.41K | 2.01M | 1.16M | 2.16M | 2.83M | 6.64M | 685.63K | 417.05K | 205.95K | 166.81K | -0.69 | -0.40 |
| Interest Expense | 23.19M | 20.18M | 11.80M | 7.60M | 6.56M | 6.96M | 7.51M | 7.89M | 8.90M | 9.72M | 11.43M | 9.67M |
| Depreciation & Amortization | 54.67M | 44.31M | 30.63M | 21.61M | 14.98M | 12.35M | 12.36M | 9.48M | 8.83M | 8.21M | 23.56M | 4.53M |
| EBITDA | -76.02M | 28.29M | 12.87M | 132.94M | 49.86M | 64.13M | 69.38M | 79.22M | 76.06M | 80.42M | 79.44M | 53.71M |
| EBITDA Ratio | -12.67% | 7.56% | 6.77% | 17.17% | 11.74% | 13.86% | 14.20% | 18.36% | 18.44% | 18.26% | 15.55% | 12.07% |
| Operating Income | -146.82M | -396.06K | 6.66M | 163.78M | 44.96M | 45.32M | 49.71M | 60.65M | 60.02M | 60.43M | 55.88M | 46.74M |
| Operating Income Ratio | -24.47% | -0.07% | 1.26% | 15.27% | 9.14% | 9.45% | 10.17% | 13.65% | 13.86% | 12.86% | 10.94% | 11.01% |
| Total Other Income/Expenses | -1.70M | 14.99K | -37.35M | 1.93M | 2.65M | -758.02K | -44.37K | 1.33M | 1.11M | 2.06M | 763.20K | -3.88M |
| Income Before Tax | -148.52M | -29.34M | -30.69M | 109.89M | 28.05M | 44.56M | 49.67M | 61.79M | 61.13M | 62.49M | 56.64M | 42.86M |
| Income Before Tax Ratio | -24.75% | -5.38% | -5.82% | 10.25% | 5.70% | 9.29% | 10.16% | 13.91% | 14.12% | 13.30% | 11.09% | 10.09% |
| Income Tax Expense | -1.23M | -14.41M | -7.65M | 11.60M | 2.90M | 7.76M | 3.24M | 9.76M | 9.65M | 9.18M | 8.60M | 7.09M |
| Net Income | -147.42M | -14.94M | -23.04M | 98.07M | 28.05M | 39.25M | 47.60M | 51.98M | 51.24M | 53.38M | 48.04M | 35.77M |
| Net Income Ratio | -24.57% | -2.74% | -4.37% | 9.14% | 5.71% | 8.18% | 9.74% | 11.70% | 11.83% | 11.36% | 9.41% | 8.42% |
| EPS | -0.51 | -0.05 | -0.08 | 0.34 | 0.10 | 0.14 | 0.20 | 0.24 | 0.24 | 0.25 | 0.22 | 0.17 |
| EPS Diluted | -0.51 | -0.05 | -0.08 | 0.34 | 0.10 | 0.14 | 0.20 | 0.24 | 0.24 | 0.25 | 0.22 | 0.17 |
| Weighted Avg Shares Out | 289.05M | 289.04M | 292.47M | 292.73M | 285.61M | 285.61M | 237.65M | 215.15M | 215.21M | 214.72M | 214.41M | 212.82M |
| Weighted Avg Shares Out (Dil) | 289.05M | 289.04M | 292.47M | 292.73M | 285.61M | 288.40M | 237.68M | 215.16M | 215.23M | 214.73M | 214.41M | 212.82M |
Source: https://incomestatements.info
Category: Stock Reports